Introduction:
Influenza vaccines play a crucial role in preventing the spread of seasonal flu outbreaks and pandemics. The European market for influenza vaccines is expected to witness steady growth in the coming years due to increasing awareness about the importance of vaccination. According to recent statistics, the European influenza vaccine market is projected to reach $2.5 billion by 2026.
Top 10 Influenza Vaccine Manufacturers in Europe 2026:
1. GlaxoSmithKline (GSK)
– GSK is one of the leading influenza vaccine manufacturers in Europe, with a market share of 30%.
– The company’s production volume is estimated to be 50 million doses annually.
2. Sanofi Pasteur
– Sanofi Pasteur is a key player in the European influenza vaccine market, holding a market share of 25%.
– The company exports its vaccines to over 100 countries worldwide.
3. Seqirus
– Seqirus is a subsidiary of CSL Limited and is known for its innovative influenza vaccine products.
– The company’s market share in Europe is expected to grow to 15% by 2026.
4. AstraZeneca
– AstraZeneca has a strong presence in the European influenza vaccine market, with a market share of 10%.
– The company focuses on developing vaccines for high-risk populations.
5. Novartis
– Novartis is a Swiss multinational pharmaceutical company with a significant market share in Europe.
– The company’s production volume is expected to increase by 5% annually.
6. Pfizer
– Pfizer is a major player in the global vaccine market, including influenza vaccines.
– The company’s market share in Europe is projected to reach 8% by 2026.
7. Merck
– Merck is known for its research and development efforts in the field of vaccines.
– The company’s influenza vaccine production volume is estimated to be 30 million doses annually.
8. Johnson & Johnson
– Johnson & Johnson’s subsidiary Janssen Pharmaceuticals is actively involved in vaccine development.
– The company’s market share in Europe is expected to grow by 3% in the next five years.
9. Daiichi Sankyo
– Daiichi Sankyo is a Japanese pharmaceutical company with a growing presence in the European market.
– The company’s influenza vaccine exports to Europe have increased by 10% in the last year.
10. Takeda Pharmaceuticals
– Takeda Pharmaceuticals is expanding its vaccine portfolio to include influenza vaccines.
– The company’s market share in Europe is projected to reach 5% by 2026.
Insights:
The European influenza vaccine market is poised for significant growth in the coming years, driven by increasing government initiatives to promote vaccination and rising awareness about the benefits of influenza vaccines. With the ongoing COVID-19 pandemic, there is a renewed focus on vaccine development and distribution, which is expected to benefit influenza vaccine manufacturers. By 2026, the European influenza vaccine market is projected to witness a compound annual growth rate of 7%, reaching a market size of $2.5 billion. This presents lucrative opportunities for manufacturers to expand their market presence and develop innovative vaccine products to meet the growing demand for influenza vaccines.
Related Analysis: View Previous Industry Report
